Johnson & Johnson Vision Receives Approval in Canada for Acuvue Abiliti 1-Day Lenses
Johnson & Johnson Vision received approval from Health Canada for Acuvue Abiliti 1-Day Soft Therapeutic Lenses for Myopia Management. Abiliti 1-Day lenses are a new option of daily wear, single-use, disposable lenses that have the potential to slow the progression of myopia and are specifically designed for children who are 7 to 12 years old at the start of treatment.1,3
“The approval from Health Canada for Acuvue Abiliti 1-Day lenses marks another major step forward in our collaborative efforts with parents and eye care professionals to reshape the future of myopia,” Xiao-Yu Song, MD, PhD, Global Head of Research & Development, Johnson & Johnson Vision, said in a company news release. “Our researchers and scientists specifically designed Abiliti 1-Day to be a novel soft therapeutic lens with the potential to slow the progression of myopia in children.”
Abiliti 1-Day lenses are not traditional concentric ring presbyopic design lenses.1 Abiliti 1-Day lenses are a innovation specifically designed to slow myopia progression in children and have been shown to reduce axial elongation by 0.105mm on average over a 6-month period.4 The lenses are built from silicone hydrogel (senofilcon A) lens material, the same material as Acuvue Oasys 1-Day contact lenses, which have never been beaten in comfort.2
The company also announced that each annual purchase of an Abiliti product would provide a free comprehensive eye health exam to a child in need through Sight For Kids—a joint program from Johnson & Johnson Vision and the not-for-profit Lions Clubs International Foundation (LCIF). Sight For Kids is one of the largest-known, school-based eye health programs that mobilizes Lions and eye care professionals to provide comprehensive eye health services in low-income schools around the world.
Abiliti 1-Day lenses are expected to become available in select areas of Canada starting as early as this year and expanding beyond in 2022. Parents and eye care professionals who want more information can visit www.seeyourabiliti.com.
References
1JJV Data on file, 2021. Development of Optical Design of ACUVUE® Abiliti™ 1-Day Soft Therapeutic Lenses for Myopia Management.
2JJV Data on file 2021. Stand-alone Performance Claims; ACUVUE® Abiliti™ 1-Day Soft Therapeutic Lenses for Myopia Management.
3JJV Data on File 2021. Mechanical Design of ACUVUE® Abiliti™ 1-Day Soft Therapeutic Lenses for Myopia Management- Effect on Fit and Handling.
4JJV Data on file, 2021. Efficacy of ACUVUE® Abiliti™ 1-Day Soft Therapeutic Lenses for Myopia Management: Comparative Claims vs. Single Vision and Dual Focus Lenses.
5Data on File 2021. Menicon Design History file.
6Flitcroft DI et al. IMI–Defining and classifying myopia: a proposed set of standards for clinical and epidemiologic studies. Invest Ophthalmol Vis Sci. 2019;60:M20-30.
7Donovan L, Sankaridurg P, Ho A et al. Myopia progression rates in urban children wearing single-vision spectacles. OVS 2012;89(1):27-32.
8Pärssinen O, Kauppinen M. Risk factors for high myopia: a 22-year follow-up study from childhood to adulthood. Acta Ophthalmologica. 2019;97(5):510-518.
9Holy C, Kulkarni K, Brennan NA. Predicting Costs and Disability from the Myopia Epidemic – A Worldwide Economic and Social Model. Invest Ophthalmol Vis Sci.2019;60(9):5466-5466.
10Holden BA, Fricke TR, Wilson DA, Jong M, Naidoo K, et al. Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 to 2050. Ophthalmol. 2016;123(5):1036-1042. doi: 10.1016/j.ophtha.2016.01.006.
11Hu Y, Ding X, Guo X, Chen Y, Zhang J, He M. Association of Age at Myopia Onset with Risk of High Myopia in Adulthood in a 12-Year Follow-up of a Chinese Cohort. JamaOphthalmol. 2020;138(11):1129-1134. doi:10.1001/jamaophthalmol.2020.3451.